Purdue Pharma and lawyers representing local governments each stated Sunday that they’re inquisitive about persevering with negotiations to settle lawsuits over the losses of the opioid crisis a day after two state attorneys’ generals advised colleagues that their discussions with the corporate have been at a deadlock and that they expected the corporate to file imminently for bankruptcy.
The statements add one other layer of uncertainty to attempts to strike a deal with an organization that’s portrayed as a prime villain within the national opioid crisis.
In an announcement, the corporate mentioned, “negotiations continue, and we remain dedicated to a decision that genuinely advances the public interest.”
The corporate mentioned it’s ready to defend itself in litigation, however, that “Purdue Pharma considers a settlement that benefits the American public now is a much better path than years of extravagant litigation and appeals.”
A company spokeswoman declined to reply additional questions about whether or not and with whom any negotiations are now taking place.
Earlier in the day, Paul Hanly, a lead lawyer for the group of native governments, unions, hospitals, and others suing the drug trade in federal court stated in a statement that any breakdown in talks didn’t characterize his group of shoppers.
Those plaintiffs, he said, “will proceed to explore resolution of our purchasers’ claims in opposition to Purdue and the Sacklers, whether or not with or without the states and inside or without bankruptcy court.”
A bankruptcy filing, if it occurs, could change the landscape instantly for a complicated series of lawsuits.